Rohto Pharmaceutical Co (4527) AI Stock Analysis

• Market Cap: ¥480.22B
• Dividend Yield: 1.93%
• Average Volume (3M): 1.27M
• Price to Earnings (P/E): 15.2
• Beta (1Y): 0.58
• Revenue Growth: 13.95%
• EPS Growth: 0.37%
• Country: JP
• Employees: 7,259
• Sector: Healthcare
• Sector Strength: 39
• Industry: Household & Personal Products
• EPS (TTM): 27.38
• Shares Outstanding: 236,178,310
• 10 Day Avg. Volume: 862,370
• 30 Day Avg. Volume: 1,273,113
• PEG Ratio: 3.06
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,689.97
• Price Target Upside: 30.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 69 Neutral
• Price Target: ¥2,261.00 ▲(9.31%Upside)

Rohto Pharmaceutical's strong financial performance is the most significant factor, indicating a well-managed company with a robust market position. However, technical indicators suggest bearish momentum, which dampens the overall score. The valuation is reasonable, providing a balance of growth and income potential.

Rohto Pharmaceutical Co Business Overview & Revenue Model

Company Description

Rohto Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is a leading company in the healthcare and pharmaceutical sectors. Established in 1949, the company is renowned for its diverse range of products, including over-the-counter (OTC) medicines, skincare products, eye care products, and health supplements. Rohto's commitment to innovation and quality has allowed it to expand its market presence not only in Japan but also internationally.

How the Company Makes Money

Rohto Pharmaceutical Co. generates revenue primarily through the sale of its broad portfolio of healthcare products. The company's key revenue streams include its OTC medicines such as cold remedies, gastrointestinal medications, and topical treatments. Additionally, Rohto capitalizes on its strong brand presence in the skincare and personal care markets, offering a variety of products ranging from moisturizers to acne treatments. The eye care segment, which includes eye drops and contact lens care solutions, also contributes significantly to its revenue. Rohto has established strategic partnerships and distribution networks globally, allowing it to penetrate and expand in international markets, further enhancing its earnings potential.

Rohto Pharmaceutical Co Financial Statement Overview

Summary

Rohto Pharmaceutical exhibits strong financial health, with solid revenue growth, robust profit margins, a stable balance sheet, and effective cash flow management. These metrics indicate a well-managed company with a strong market position.

Income Statement

Rohto Pharmaceutical has shown a consistent upward trend in revenue growth, with a notable increase of 13.94% in the latest year. Gross profit margin remains strong at 54.88%, and the net profit margin is stable at 10.05%. Despite a slight dip in EBIT margin to 12.46%, the company maintains healthy profitability metrics overall.

Balance Sheet

The company's balance sheet is robust, highlighted by a low debt-to-equity ratio of 0.19, indicating low leverage and financial stability. The equity ratio is healthy at 61.64%, suggesting a strong capital structure. Return on equity stands at 11.92%, showcasing efficient use of equity to generate profit.

Cash Flow

Rohto Pharmaceutical has demonstrated solid cash flow management with a free cash flow growth rate of 9.90%. The operating cash flow to net income ratio is healthy at 1.19, indicating strong cash generation relative to net income. The free cash flow to net income ratio is also favorable at 0.90.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	295.57B	308.63B	270.84B	238.66B	199.65B	181.05B
Gross Profit	168.86B	169.38B	157.29B	137.42B	116.49B	106.73B
EBITDA	45.56B	56.42B	50.40B	41.34B	35.81B	28.61B
Net Income	29.59B	31.00B	30.94B	26.38B	21.13B	16.74B
Balance Sheet
Total Assets	403.86B	421.88B	346.18B	309.68B	274.63B	225.79B
Cash, Cash Equivalents and Short-Term Investments	61.71B	77.16B	89.21B	79.95B	72.79B	52.96B
Total Debt	38.81B	50.22B	10.49B	11.69B	21.38B	8.10B
Total Liabilities	136.68B	150.43B	99.14B	94.60B	90.80B	69.18B
Stockholders Equity	256.07B	260.10B	246.32B	209.57B	178.28B	155.91B
Cash Flow
Free Cash Flow	0.00	27.84B	25.33B	21.02B	15.92B	9.70B
Operating Cash Flow	0.00	36.92B	34.24B	30.92B	27.25B	20.01B
Investing Cash Flow	0.00	-57.55B	-16.32B	-13.18B	-16.41B	-10.24B
Financing Cash Flow	0.00	3.70B	-13.78B	-16.20B	3.47B	-2.35B

Rohto Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2068.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4527, the sentiment is Neutral. The current price of 2068.5 is above the 20-day moving average (MA) of 2058.33, below the 50-day MA of 2138.40, and below the 200-day MA of 2624.79, indicating a neutral trend. The MACD of -13.99 indicates Negative momentum. The RSI at 49.17 is Neutral, neither overbought nor oversold. The STOCH value of 78.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4527.

Rohto Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4527	69 Neutral	¥480.22B	15.20	12.05%	1.93%	13.95%	0.37%
4927	66 Neutral	$279.63B	37.44	4.49%	3.32%	-0.74%	-25.66%
4922	64 Neutral	$336.37B	57.42	2.08%	2.37%	4.63%	-60.17%
4911	60 Neutral	¥1.05T	496.62		1.52%	-1.33%	-139.30%
4967	60 Neutral	$390.25B	36.51	5.17%	1.67%	-8.36%	-38.35%
4912	59 Neutral	$398.82B	18.74	7.58%	2.04%	2.30%	33.87%
Sector *	49 Neutral	AU$2.50B	4.42	-64.25%	2.77%	36.51%	13.14%

Rohto Pharmaceutical Co Corporate Events

Rohto Pharmaceutical Announces Dividend Increase

Rohto Pharmaceutical Co., Ltd. announced a resolution to pay dividends from retained earnings, with a record date of March 31, 2025. The year-end dividend per share is set at 20 yen, consistent with the most recent forecast, and represents an increase from the previous fiscal year’s 15 yen per share. This decision reflects the company’s strong financial performance and commitment to returning value to shareholders, potentially enhancing its market position and investor confidence.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

Rohto Pharmaceutical Unveils 2025-2035 Growth Strategy

Rohto Pharmaceutical Co., Ltd. has announced its Medium- to Long-Term Growth Strategy for 2025–2035, focusing on expanding its Self-care and Professional Care domains. The strategy includes global expansion, enhancing technological capabilities, and establishing a medical business foundation. Rohto aims to achieve net sales of 415 billion yen by 2030, with a focus on delivering new value in eye and skincare, advancing research in Phyto-Science, and developing new ophthalmic and regenerative medicine products. The company also plans to increase dividends sustainably while maintaining a strong financial structure.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

Rohto Pharmaceutical Reports FY2025 Financial Results with Increased Sales and Dividends

Rohto Pharmaceutical Co. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a 14% increase in net sales to ¥308,625 million. Despite the rise in sales, the company experienced a decline in operating and ordinary income by 2.8% and 4.7% respectively, attributed to various market challenges. The company also announced an increase in annual dividends, reflecting a commitment to shareholder returns. The financial results indicate a strategic focus on expanding its market presence and enhancing corporate value through acquisitions, as evidenced by the inclusion of 46 new subsidiaries.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

Rohto Pharmaceutical Announces Leadership Changes to Drive Future Growth

Rohto Pharmaceutical Co., Ltd. announced significant leadership changes, including the appointment of Hidetoshi Segi as the new President and Chief Operating Officer, effective after the upcoming shareholders’ meeting. These changes are expected to strengthen the company’s management foundation and drive future growth, with Segi’s leadership focusing on both existing and new business development.